Actively Recruiting
A Phase 2 Randomized Open-Label Trial Evaluating LY3938577 Compared to Degludec in Adults With Type 2 Diabetes Previously Treated With Basal Insulin
Led by Eli Lilly and Company · Updated on 2026-05-22
100
Participants Needed
26
Research Sites
4 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating the effectiveness and safety of LY3938577 compared to degludec in people with type 2 diabetes who have been previously treated with basal insulin. This Phase 2 trial aims to understand how well LY3938577 works in managing blood sugar levels in this patient population. The study is sponsored by Eli Lilly and Company and participation lasts about 26 weeks. Participants are randomly assigned to receive either LY3938577 or degludec, both given by subcutaneous injection. The study compares these two treatments to observe differences in glucose control and safety. The trial design is open-label, meaning both participants and researchers know which treatment is given. Throughout the study, researchers will monitor changes in blood sugar levels, specifically the time glucose remains in the target range of 70 to 180 mg/dL from baseline to week 20. Other measures include changes in hemoglobin A1c and drug concentration levels. Safety and treatment effects are assessed at regular intervals during the 26-week participation period.
CONDITIONS
Brief Title
A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Have type 2 diabetes
- Are receiving at least 20 units and no more than 55 units of basal insulin per day at screening
- Have hemoglobin A1c (HbA1c) between 7.5% and 10.5% inclusive
- Have a body mass index (BMI) of 20 or higher and less than 35 kg/m2
You will not qualify if you...
- Have type 1 diabetes
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 20 weeks
Participants receive either LY3938577 or degludec via subcutaneous injection as part of the study treatment.
Regular visits during treatment period
Trial Site Locations
Total: 26 locations
1
Tucson Clinical Research Institute
Tucson, Arizona, United States, 85712
Active, Not Recruiting
2
Encompass Clinical Research
Spring Valley, California, United States, 91978
Active, Not Recruiting
3
University Clinical Investigators, Inc.
Tustin, California, United States, 92780
Actively Recruiting
4
Tampa Bay Medical Research
Clearwater, Florida, United States, 33761
Actively Recruiting
5
Encore Medical Research
Hollywood, Florida, United States, 33024
Active, Not Recruiting
6
Clinical Research of Central Florida
Lakeland, Florida, United States, 33805
Completed
7
Encore Medical Research - Weston
Weston, Florida, United States, 33331
Actively Recruiting
8
Iowa Diabetes and Endocrinology Research Center
West Des Moines, Iowa, United States, 50266
Active, Not Recruiting
9
Washington University School of Medicine
St Louis, Missouri, United States, 63110
Completed
10
Accellacare - Wilmington
Wilmington, North Carolina, United States, 28401
Actively Recruiting
11
AMR Clinical
Norman, Oklahoma, United States, 73069
Completed
12
Tribe Clinical Research, LLC
Greenville, South Carolina, United States, 29607
Completed
13
Holston Medical Group
Bristol, Tennessee, United States, 37620
Actively Recruiting
14
Texas Diabetes & Endocrinology, P.A.
Austin, Texas, United States, 78749
Active, Not Recruiting
15
Velocity Clinical Research, Dallas
Dallas, Texas, United States, 75230
Active, Not Recruiting
16
Juno Research
Houston, Texas, United States, 77040
Actively Recruiting
17
Southern Endocrinology Associates
Mesquite, Texas, United States, 75149
Completed
18
Consano Clinical Research, LLC
Shavano Park, Texas, United States, 78231
Completed
19
Texas Valley Clinical Research
Weslaco, Texas, United States, 78596
Actively Recruiting
20
Chrysalis Clinical Research
St. George, Utah, United States, 84790
Actively Recruiting
21
Cicemo Srl
Buenos Aires, Argentina, 1424
Actively Recruiting
22
CIPREC
Buenos Aires, Argentina, C1119ACN
Actively Recruiting
23
Mautalen Salud e Investigación
Buenos Aires, Argentina, C1128AAF
Actively Recruiting
24
Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada
Buenos Aires, Argentina, C1425AGC
Actively Recruiting
25
Instituto Centenario
CABA, Argentina, 1204
Actively Recruiting
26
Instituto Médico Catamarca IMEC
Rosario, Argentina, 2000
Actively Recruiting
Research Team
T
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
P
Physicians interested in becoming principal investigators please contact
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here